Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stinchcombe

Showing results (511-520 of 575) with videos related to

Pageof 58
Sort By:
JAMA Network Open|October 24, 2024
Prognostic Factors in Limited-Stage Small Cell Lung Cancer: A Secondary Analysis of CALGB 30610-RTOG 0538Michael K Farris, Michael D Mix, Xiaofei Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
Development, Review, and Activation of Thoracic Oncology Investigator-Initiated TrialsDavid E Gerber, Claire R Wynters, Tanushree Prasad, et al.
Nature Communications|January 22, 2020
Distinctive phenotypes and functions of innate lymphoid cells in human decidua during early pregnancyOisín Huhn, Martin A Ivarsson, Lucy Gardner, et al.
ESMO Open|March 11, 2023
A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutationsL C Villaruz, X Wang, E M Bertino, et al.
Journal for Immunotherapy of Cancer|February 4, 2025
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysisCameron Wood, Liliana Lyniv, James M Isaacs, et al.
The Oncologist|September 20, 2020
Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non-Small Cell Lung Cancer in CALGB 9730 (Alliance A151729)Melisa L Wong, Junheng Gao, Gita Thanarajasingam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2019
Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating <i>RET</i> Alterations and Oncogenic Signaling Pathway AberrationsThereasa A Rich, Karen L Reckamp, Young Kwang Chae, et al.
Molecular Biology and Evolution|January 15, 2025
Rapid Parallel Adaptation in Distinct Invasions of Ambrosia Artemisiifolia Is Driven by Large-Effect Structural VariantsPaul Battlay, Samuel Craig, Andhika R Putra, et al.
Scientific Data|April 11, 2019
Nutrient, pigment, suspended matter and turbidity measurements in the Belgian part of the North SeaJonas Mortelmans, Klaas Deneudt, André Cattrijsse, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 1, 2011
A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancerThomas E Stinchcombe, Amy H Peterman, Carrie B Lee, et al.
Pageof 58

Showing results (511-520 of 575) with videos related to

Sort By:
Pageof 58
JAMA Network Open|October 24, 2024
Prognostic Factors in Limited-Stage Small Cell Lung Cancer: A Secondary Analysis of CALGB 30610-RTOG 0538Michael K Farris, Michael D Mix, Xiaofei Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
Development, Review, and Activation of Thoracic Oncology Investigator-Initiated TrialsDavid E Gerber, Claire R Wynters, Tanushree Prasad, et al.
Nature Communications|January 22, 2020
Distinctive phenotypes and functions of innate lymphoid cells in human decidua during early pregnancyOisín Huhn, Martin A Ivarsson, Lucy Gardner, et al.
ESMO Open|March 11, 2023
A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutationsL C Villaruz, X Wang, E M Bertino, et al.
Journal for Immunotherapy of Cancer|February 4, 2025
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysisCameron Wood, Liliana Lyniv, James M Isaacs, et al.
The Oncologist|September 20, 2020
Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non-Small Cell Lung Cancer in CALGB 9730 (Alliance A151729)Melisa L Wong, Junheng Gao, Gita Thanarajasingam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2019
Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating <i>RET</i> Alterations and Oncogenic Signaling Pathway AberrationsThereasa A Rich, Karen L Reckamp, Young Kwang Chae, et al.
Molecular Biology and Evolution|January 15, 2025
Rapid Parallel Adaptation in Distinct Invasions of Ambrosia Artemisiifolia Is Driven by Large-Effect Structural VariantsPaul Battlay, Samuel Craig, Andhika R Putra, et al.
Scientific Data|April 11, 2019
Nutrient, pigment, suspended matter and turbidity measurements in the Belgian part of the North SeaJonas Mortelmans, Klaas Deneudt, André Cattrijsse, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 1, 2011
A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancerThomas E Stinchcombe, Amy H Peterman, Carrie B Lee, et al.
Pageof 58